3 May 2021

Tjoapack invests in automated injectables packaging capabilities

PDF 95 kB

At Tjoapack we’re committed to ensuring we consistently bolster our offering and deliver the efficient and flexible services that our clients expect.

That is why we are excited to announce our most recent investment into our automated injectables packaging capabilities which will begin operations in 2021!

Learn more about our current syringe and vial packaging offerings here

Content provided by our supplier


  • NL
  • 2017
    On CPHI since
  • 2
  • 250 - 499
Company types
Contract Service
Distributor/Import Export

Other Content from TJOAPACK LLC (12)

  • News Tjoapack invests over €10m into Etten-Leur facility

    Global contract packaging organisation (CPO), Tjoapack, has announced a €10m+ investment into its packaging and supply chain facility in Etten-Leur, Netherlands over the next two years.
  • Brochure Tjoapack invests over €10m into Etten-Leur facility

    At Tjoapack we're dedicated to shaping the future of the pharmaceutical supply chain which is why we're delighted to announce that over the next two years we'll be expanding our facility in Etten-Leur from 8,400sq.m. to 11,500 sq.m.

    The investment of over €10m will more than double our primary packaging capacity for oral solids, as well as bolster our warehousing and cold chain capabilities to meet demand for our value-added logistics services.

    Read more here
  • News Tjoapack invests in automated injectables packaging capabilities

    Global contract packaging organisation (CPO), Tjoapack is investing in its automated packaging capabilities to meet growing customer demand for pre-filled syringes and vials.
  • News Tjoapack announces investment from Ampersand Capital Partners

    Tjoapack Netherlands B.V., a global contract packaging organisation (CPO) for the pharmaceutical industry, today announced a majority investment from Ampersand Capital Partners, a private equity firm that specializes in partnering with entrepreneur-led healthcare companies.  Ampersand’s investment will be used to expand Tjoapack’s capabilities to meet growing industry demand for high quality pharmaceutical packaging services across different dosage forms.
  • Brochure Tjoapack receives investment from Ampersand Capital Partners

    We're delighted to announce today that Tjoapack has received a majority investment from Ampersand Capital Partners, a private equity firm specialising in the pharmaceutical and healthcare industry. The investment will allow us to continue to expand our capabilities and capacity to meet rising customer demand, as well as help support us in achieving our long-term strategic growth.

    In addition to the investment, Dexter Tjoa, our Director Corporate Strategy, has been appointed as the new CEO taking over from our founder, Eric Tjoa. Eric will maintain a seat on the Board alongside our new investors.

    Read more about the investment here
  • News Tjoapack secures investment to increase pharma packaging capabilities

    The CPO has immediate plans to expand its automated packaging capabilities, including for injectable products.
  • News Tjoapack and Veratrak launch first live blockchain tool

    Secure data sharing across the pharmaceutical industry.
  • Whitepaper Postponement packaging whitepaper

    Postponement packaging is the practice of keeping products in a semi-finished, market agnostic state, and only finalising them when there is a specific market demand.

    Used strategically, it will allow pharmaceutical manufacturers to respond to market-related fluctuation as well as variations in packaging requirements. In addition, postponement will enable pharma companies to lower working capital by reducing finished goods inventories, avoid repackaging work, reduce waste across the supply chain, and shorten their return on investment cycle.

    In this whitepaper, Dr Anita Paz, Innovation Consultant and Dexter Tjoa, CEO (formerly Director Corporate Strategy) at Tjoapack, outline the postponement packaging principle and the key points to consider before implementing it as a supply chain strategy. They also discuss how this approach can be applied to different product portfolios and the benefits that adoption could bring to the pharmaceutical industry.

    For more information on postponement packaging visit
  • News The 6-month FMD countdown - are you ready?

    With only 6 months left in which to become EU FMD-compliant, how can companies make the best use of their now limited options?
  • News Tjoapack wins packaging contract for bladder cancer detection products

    Tjoapack to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
  • News Investing in blistering capabilities to boost flexibility

    Postponement printing is presenting interesting benefits for the pharmaceutical supply chain.